Side effects/toxicity with R-223Side effects/toxicity with R-223When you are starting a patient on R-223, please list the most important things you counsel the patient about related to potential side effects or toxicity. To what extent, if any, do you believe R-223 causes myelosuppression?
Dan TD et al. Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies. Am J Clin Oncol 2015;[Epub ahead of print]. Abstract Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397-406. Abstract Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: An evaluation of its safety. Expert Opin Drug Saf 2015;[Epub ahead of print]. Abstract Parker C et al. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. Genitourinary Cancers Symposium 2015;Abstract 195. Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. Abstract Sartor O et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738-46. Abstract |